# Breakthrough Blood Test for Alzheimer’s Detection! Newsy: Alzheimer’s News Weekly Published: 2025-10-14T21:53:00.421Z Source: https://newsyai.com/edition/50f5fc62-a6f1-4b89-9799-83eea9ec9bb6 Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- # The Alzheimer’s Treatment Briefing Weekly roundup of the most important developments in Alzheimer’s care and research Coverage period: October 8–14, 2025 (U.S.) — ## Top stories (ranked) 1) FDA clears a simple primary‑care blood test to quickly “rule out” Alzheimer’s‑type brain changes - What’s new - On October 13, the FDA cleared Roche/Eli Lilly’s Elecsys pTau181 blood test for adults 55+ who present with memory or thinking concerns in primary care. In a 312‑person study, a negative result ruled out Alzheimer’s‑type brain changes with 97.9% accuracy. Because more than 4,500 Roche analyzers are already in U.S. labs, this could roll out rapidly. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - Why this matters - Faster answers, fewer invasive tests: Many people can be told—via a regular blood draw—that Alzheimer’s‑type changes are unlikely, avoiding spinal taps or costly PET scans. - Shorter path to treatment: Those who still screen positive can be prioritized for confirmatory testing and earlier talks about disease‑slowing medicines (e.g., lecanemab/Leqembi, donanemab/Kisunla). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) 2) “Weight‑loss” drugs and Alzheimer’s: big Phase 3 semaglutide results are near - What’s new - A detailed preview this week set expectations for two large Phase 3 trials testing semaglutide (the active ingredient in Ozempic/Wegovy) in early Alzheimer’s disease. Prior lab and real‑world data hint GLP‑1 drugs might calm brain inflammation and protect nerve cells; now we’re close to learning whether that translates into slower decline. ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai)) - Why this matters - A different tool, if it works: Even a modest benefit could add a safer, easier‑to‑use option that complements plaque‑clearing antibodies—or help people who aren’t candidates for them. A negative readout would still sharpen our understanding of what truly moves the needle in Alzheimer’s. ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai)) 3) New “fast MRI” study suggests scans can be cut to one‑third the time—freeing capacity for treatment work‑ups - What’s new - A University College London team reported on October 13 that a streamlined MRI protocol can deliver diagnostic‑quality brain scans in roughly one‑third the usual time. The group estimates memory clinics could at least double daily scan throughput with no hardware upgrades. ([uclhospitals.brc.nihr.ac.uk](https://www.uclhospitals.brc.nihr.ac.uk/news/faster-mri-scans-offer-new-hope-dementia-diagnosis?utm_source=openai)) - Why this matters - Quicker, cheaper MRI means more people can be safely evaluated before starting and while monitoring disease‑slowing antibody treatments (which require MRI safety checks). Shorter scans are also easier for patients who struggle to lie still. ([uclhospitals.brc.nihr.ac.uk](https://www.uclhospitals.brc.nihr.ac.uk/news/faster-mri-scans-offer-new-hope-dementia-diagnosis?utm_source=openai)) 4) Access watch: Part D plan options are shrinking, which can affect Alzheimer’s medication coverage - What’s new - Heading into the Oct 15–Dec 7 Medicare open‑enrollment window, the number of standalone Part D plan choices continues to drop, and some zero‑premium options for low‑income beneficiaries are disappearing. Average premiums may fall, but some plans raise deductibles or tighten formularies. ([apnews.com](https://apnews.com/article/8cf0b1460e84367cdba7002147165a50?utm_source=openai)) - Why this matters - Coverage details determine out‑of‑pocket costs for Alzheimer’s medicines and the supportive drugs and scans used with them. People on fixed incomes may need to switch plans to keep costs reasonable. Reviewing options early is key. ([apnews.com](https://apnews.com/article/8cf0b1460e84367cdba7002147165a50?utm_source=openai)) — ## What this means in plain language - A regular blood test your primary‑care clinician can order may soon tell many people with memory worries that Alzheimer’s‑type changes are unlikely—saving time, money, and invasive testing. For those who still screen positive, it speeds the path to confirmatory tests and treatment talks. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - Results from “Ozempic/Wegovy‑like” drugs in Alzheimer’s are coming soon. If they help, we’ll have an easier add‑on to today’s options; if not, we’ll know to focus efforts elsewhere. ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai)) - Faster MRI could help clinics handle more evaluations and safety checks for people considering disease‑slowing antibodies—without new scanners. ([uclhospitals.brc.nihr.ac.uk](https://www.uclhospitals.brc.nihr.ac.uk/news/faster-mri-scans-offer-new-hope-dementia-diagnosis?utm_source=openai)) - Medicare drug‑plan choices are tightening. That may change which plans best cover Alzheimer’s medicines and required monitoring. Shop carefully during open enrollment. ([apnews.com](https://apnews.com/article/8cf0b1460e84367cdba7002147165a50?utm_source=openai)) — ## Quick guidance for patients and caregivers this week - Ask about blood‑based testing - Will Elecsys pTau181 be available through your health system? How will a “rule‑out” result guide next steps? ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - If you’re considering disease‑slowing therapy (Leqembi/Kisunla) - Even with faster blood tests, you’ll still need careful MRI safety checks and shared decision‑making with a specialist. Faster MRI protocols could help reduce bottlenecks at some centers. ([uclhospitals.brc.nihr.ac.uk](https://www.uclhospitals.brc.nihr.ac.uk/news/faster-mri-scans-offer-new-hope-dementia-diagnosis?utm_source=openai)) - Prepare for Medicare open enrollment (Oct 15–Dec 7) - Compare Part D plans early; look at drug formularies, deductibles, and prior‑auth rules relevant to your meds and MRI/PET needs. Free help: Medicare.gov Plan Finder and your state’s SHIP program. ([apnews.com](https://apnews.com/article/8cf0b1460e84367cdba7002147165a50?utm_source=openai)) — ## Sources and further reading - Reuters: FDA clears Roche/Lilly Elecsys pTau181 blood test for primary‑care use (Oct 13, 2025). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - Financial Times analysis: Semaglutide Phase 3 Alzheimer’s trials nearing results—what to watch (Oct 13, 2025). ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai)) - UCLH BRC: “Faster MRI scans offer new hope for dementia diagnosis” (Oct 13, 2025). ([uclhospitals.brc.nihr.ac.uk](https://www.uclhospitals.brc.nihr.ac.uk/news/faster-mri-scans-offer-new-hope-dementia-diagnosis?utm_source=openai)) - Alzheimer’s Society post echoing UCL findings (Oct 13, 2025). ([alzheimers.org.uk](https://www.alzheimers.org.uk/news/2025-10-13/faster-mri-scans-offer-new-hope-dementia-diagnosis?utm_source=openai)) - AP: “Prescription drug coverage options are shrinking for Medicare shoppers” (Oct 11, 2025). ([apnews.com](https://apnews.com/article/8cf0b1460e84367cdba7002147165a50?utm_source=openai)) — Want us to keep a close eye on the first semaglutide readouts, anti‑tau antibodies, or how fast MRI and blood tests are being adopted by major U.S. systems? Tell us what to add to next week’s watchlist.